Suppr超能文献

肝脏疾病与 HPLC 定量检测双涎酸转铁蛋白在重度酒精使用中的应用:病例系列研究。

Liver disease and HPLC quantification of disialotransferrin for heavy alcohol use: a case series.

机构信息

Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston, South Carolina 29425, USA.

出版信息

Alcohol Clin Exp Res. 2010 Nov;34(11):1956-60. doi: 10.1111/j.1530-0277.2010.01285.x.

Abstract

BACKGROUND

It had previously been suggested that individuals with cirrhosis may have a pattern of transferrin glycosylation that interferes with the interpretation of carbohydrate-deficient transferrin (CDT) testing for heavy alcohol use. The goal of this case series was to evaluate the prevalence of liver disease among individuals with poor resolution of transferrin glycoforms by high performance liquid chromatography.

METHODS

We reviewed the electronic medical records of 35 consecutive patients with poor chromatographic resolution of disialotransferrin from trisialotransferrin and recorded information on diagnosed liver disease, liver function testing, and other factors.

RESULTS

Thirty of the 35 subjects with poor chromatographic resolution of the transferrin glycoforms had sufficient data in the medical record for some estimation of liver function. Of these 30 subjects, 25 had previously diagnosed liver pathology. Of the remaining 5 subjects, 2 had liver imaging results suggestive of benign tumor; the remaining 3 had mildly elevated bilirubin and aminotransferase activity, and low albumin.

CONCLUSIONS

Liver abnormalities, but not necessarily cirrhosis, are common in individuals with poor chromatographic separation of transferrin glycoforms, which might lead to false-positive results on CDT testing. However, the chromatographic-based assay can detect this issue, minimizing the reporting of false positives, but not necessarily assisting in valid detection of heavy drinking.

摘要

背景

先前有研究提示,肝硬化患者的转铁蛋白糖基化模式可能会干扰对碳水化合物缺乏转铁蛋白(CDT)检测的解读,以用于重度饮酒的评估。本病例系列研究的目的是通过高效液相色谱评估糖基化转铁蛋白色谱分辨率不佳的个体中肝脏疾病的患病率。

方法

我们回顾了 35 例连续出现双涎酸转铁蛋白色谱分辨率不佳的患者的电子病历,并记录了诊断为肝脏疾病、肝功能检测和其他因素的信息。

结果

35 例转铁蛋白糖基化谱色谱分辨率不佳的患者中,有 30 例有足够的病历数据可用于对肝功能进行某种程度的评估。在这 30 例患者中,25 例之前已被诊断为肝脏病变。其余 5 例中,2 例肝脏影像学结果提示良性肿瘤;其余 3 例胆红素和转氨酶活性轻度升高,白蛋白水平降低。

结论

肝功能异常,但不一定是肝硬化,在转铁蛋白糖基化谱色谱分辨率不佳的个体中很常见,这可能导致 CDT 检测的假阳性结果。然而,基于色谱的检测方法可以检测到这个问题,最大限度地减少假阳性的报告,但不一定有助于对重度饮酒的有效检测。

相似文献

1
Liver disease and HPLC quantification of disialotransferrin for heavy alcohol use: a case series.
Alcohol Clin Exp Res. 2010 Nov;34(11):1956-60. doi: 10.1111/j.1530-0277.2010.01285.x.
2
Relationship of Abnormal Chromatographic Pattern for Carbohydrate-Deficient Transferrin with Severe Liver Disease.
Alcohol Alcohol. 2017 Jan;52(1):24-28. doi: 10.1093/alcalc/agw069. Epub 2016 Oct 7.
5
Improved HPLC method for carbohydrate-deficient transferrin in serum.
Clin Chem. 2003 Nov;49(11):1881-90. doi: 10.1373/clinchem.2003.023341.
6
The Utility of Commonly Used Laboratory Tests to Screen for Excessive Alcohol Use in Clinical Practice.
Alcohol Clin Exp Res. 2015 Aug;39(8):1493-500. doi: 10.1111/acer.12780. Epub 2015 Jun 25.
7
Determination of carbohydrate-deficient transferrin in human serum using the Bio-Rad %CDT by HPLC test.
Clin Chim Acta. 2006 Sep;371(1-2):187-90. doi: 10.1016/j.cca.2006.03.010. Epub 2006 May 15.
8
Effect of transferrin glycation on the use of carbohydrate-deficient transferrin as an alcohol biomarker.
Alcohol Alcohol. 2013 Jul-Aug;48(4):478-82. doi: 10.1093/alcalc/agt045. Epub 2013 May 19.

引用本文的文献

1
Diagnostic and Therapeutic Approaches in Congenital Disorders of Glycosylation.
Handb Exp Pharmacol. 2025;288:211-241. doi: 10.1007/164_2025_745.
2
Co-abuse of amphetamine and alcohol harms kidney and liver.
Sci Rep. 2024 Oct 8;14(1):23400. doi: 10.1038/s41598-024-74459-5.
3
Relationship of Abnormal Chromatographic Pattern for Carbohydrate-Deficient Transferrin with Severe Liver Disease.
Alcohol Alcohol. 2017 Jan;52(1):24-28. doi: 10.1093/alcalc/agw069. Epub 2016 Oct 7.
4
Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers.
BMC Gastroenterol. 2014 May 22;14:97. doi: 10.1186/1471-230X-14-97.
5
Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease.
Alcohol Clin Exp Res. 2014 Jun;38(6):1706-11. doi: 10.1111/acer.12442. Epub 2014 May 21.

本文引用的文献

1
Alteration of protein glycosylation in liver diseases.
J Hepatol. 2009 Mar;50(3):592-603. doi: 10.1016/j.jhep.2008.12.010. Epub 2008 Dec 27.
2
Fucosylated glycoproteins as markers of liver disease.
Dis Markers. 2008;25(4-5):259-65. doi: 10.1155/2008/264594.
6
Congenital disorders of N-glycosylation including diseases associated with O- as well as N-glycosylation defects.
Pediatr Res. 2006 Dec;60(6):643-56. doi: 10.1203/01.pdr.0000246802.57692.ea. Epub 2006 Oct 25.
8
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.
J Hepatol. 2006 Jan;44(1):217-31. doi: 10.1016/j.jhep.2005.10.013. Epub 2005 Nov 9.
9
Improved HPLC method for carbohydrate-deficient transferrin in serum.
Clin Chem. 2003 Nov;49(11):1881-90. doi: 10.1373/clinchem.2003.023341.
10
The effects of ethanol on the glycosylation of human transferrin.
Glycobiology. 2003 Mar;13(3):191-8. doi: 10.1093/glycob/cwg016. Epub 2002 Nov 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验